Loading
Butterfly Network, Inc. Stock: price and insider trades · United States
1 insider bought €866k of shares over the last 90 days, the latest filed 17 Aug 2026.
Butterfly Network, Inc.: what insiders have been doing
Butterfly Network, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 108 filings signed by 24 insiders.
The record shows 5 purchases on the open market worth €5.5M, made by 2 insiders, against 53 sales worth €96.3M by 9 insiders. No amount is published for 1 filing, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 2 senior executives among the declarants. At €11.1M, the sale published on 16 July 2026 by Rothberg Jonathan M is the largest of the period (0.50% of market cap).
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 108 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 12 purchases against 110 sales. The 10-K for the year ended 31 December 2025 shows 97.6 m USD of revenue and -77.1 m USD of net income.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 17 August 2026, 62 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
245
Thresholds
n/a
Buy Volume
€10M
12 ops. · all time
Sell Volume
€101M
110 ops. · all time
Who traded when
BuySaleRothberg Jonathan M20 sales
Larry Robbins3 buys7 sales
Steve Cashman1 buy8 sales
Joseph Devivo8 sales
Nicholas Caezza6 sales
Megan Carlson5 sales
+6 other insiders
Since the insiders bought
- -15.6%Entry US$9.00 · Close 14 Oct 2026 US$7.60
- +17.1%Entry US$3.34 · Close at T+90 US$3.91
- +417.2%Entry US$1.63 · Close at T+365 US$8.43
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Butterfly Network, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$11.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,466 of 24,148 companies
27.1
score / 100
Value28
Quality26
FCF yld-0.8%
Earn yld-3.7%
EV/EBITDA·
ROE-35%
Gross mgn47%
Net mgn-79%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.55
Analyst consensus
6 analystsStrong buy
US$10.00Target US$11.17(+31%)US$15.00
Income statement
RevenueUS$97.6M
Gross profitUS$45.7M47% margin
EBITDA-US$67.4M-69% margin
Net income-US$77.1M-66.7% margin
Valuation
PER (forward)-126.7x
P/Book11.9x
Beta2.04
Balance sheet & cash
Market capUS$2.3B
Total debtUS$20.4M
Free Cash Flow-US$16M
Debt / Equity10%
Profitability & ownership
ROE-35.5%
ROA-10.5%
% insiders10.2%
% institutions62.0%
Last declaration on 15 October 2026
Declarations245 total
37,037 shares0Class A Common StockSEC:0002064832-26-000333:0
35,790 shares@ US$10.020.016% mcap3.1% of flowClass A Common StockSEC:0002064832-26-000329:0
35,790 shares@ US$10.020.015% mcap3.2% of flowClass ASEC144:0001959173-26-007288
10,114 shares@ US$8.7450.0037% mcap4.2% of flowClass A Common StockSEC:0002064832-26-000327:0
10,114 shares@ US$8.74510.0037% mcap4.4% of flowClass ASEC144:0001959173-26-007248
3,169 shares@ US$10.0210.0013% mcap0.3% of flowClass A Common StockSEC:0002064832-26-000325:1
323,020 shares@ US$10.000.13% mcap80.4% of flowClass ASEC144:0001959173-26-007086
3,169 shares@ US$10.02110.0013% mcap0.3% of flowClass ASEC144:0001959173-26-007094
78,679 shares@ US$10.000.031% mcap19.6% of flowClass ASEC144:0001959173-26-007082
2,811 shares@ US$10.000.0011% mcap0.3% of flowClass ASEC144:0001959173-26-007083
13,804 shares@ US$7.3020.0039% mcap5.1% of flowClass A Common StockSEC:0002064832-26-000321:0
140,112 shares@ US$7.3020.040% mcap12.7% of flowClass A Common StockSEC:0002064832-26-000322:0
13,804 shares@ US$7.30170.0039% mcap5.1% of flowClass ASEC144:0001959173-26-006752
140,112 shares@ US$7.30170.040% mcap12.7% of flowClass ASEC144:0001959173-26-006754
1,709 shares@ US$8.1490.0005% mcap10.0% of flowClass A Common StockSEC:0002064832-26-000312:0
250,000 shares0Class A Common StockSEC:0002064832-26-000280:0
215,233 shares@ US$9.54180.081% mcap3.5% of flowClass A Common StockSEC:0000905148-26-003784:0
500,000 shares@ US$9.23550.18% mcap8.0% of flowClass A Common StockSEC:0000905148-26-003784:1
175,300 shares@ US$8.86040.061% mcap2.7% of flowClass A Common StockSEC:0000905148-26-003784:2
824,700 shares@ US$8.69730.28% mcap12.4% of flowClass A Common StockSEC:0000905148-26-003784:3
582,500 shares@ US$8.97020.20% mcap9.0% of flowClass A Common StockSEC:0000905148-26-003784:4
115,200 shares@ US$8.67630.039% mcap59.4% of flowClass A Common StockSEC:0002064832-26-000274:0
Canonical exit: 12 Nov 2026 (T+90)
68,346 shares@ US$10.0090.027% mcap6.2% of flowClass A Common StockSEC:0002064832-26-000268:0
10,000 shares@ US$9.750.0038% mcap70.2% of flowClass ASEC144:0001959173-26-005883
68,346 shares@ US$10.00910.027% mcap6.2% of flowClass ASEC144:0001959173-26-005846
25 of 245 declarations
About Butterfly Network, Inc.
Butterfly Network, Inc. is a U.S.-based medical technology company listed on the NYSE under the ticker BFLY in the United States market. Founded in 2011 by Dr. Jonathan Rothberg, the company was built around a clear mission: democratize medical imaging by making ultrasound more affordable, portable, easier to use, and more widely accessible. Its headquarters are in Burlington, Massachusetts, and it has a commercial footprint that spans the United States and multiple international markets. For French-speaking investors, Butterfly is best viewed as a growth-stage medtech with a still-evolving commercial model and a meaningful execution story ahead.
The business centers on semiconductor-based handheld ultrasound devices, cloud software, and AI-enabled workflows. Butterfly’s core product family includes Butterfly iQ, iQ+, and the third-generation iQ3, all designed to bring whole-body point-of-care ultrasound into a compact, smartphone- and tablet-connected format. The company also offers Butterfly Move, which combines portability with cart-like stability, and more specialized solutions such as iQ+ Bladder. Beyond hardware, Butterfly is working to expand recurring revenue through software subscriptions, cloud-connected services, and ecosystem monetization via initiatives such as Butterfly Embedded and Butterfly Garden.
Read moreShow less
From a competitive standpoint, Butterfly Network targets the point-of-care ultrasound (POCUS) market, where adoption depends on device simplicity, workflow integration, clinical utility, and total cost of ownership. Its differentiation lies in its ultrasound-on-chip architecture, software-led product design, and a platform approach that can extend beyond traditional device sales. That makes Butterfly a distinct competitor versus larger, more established imaging vendors that rely on conventional ultrasound hardware. The company is pushing deeper into hospitals, outpatient settings, community care, and home-based use cases, which broadens its long-term addressable market.
Recent developments reinforce that strategic direction. Butterfly launched the iQ3 in the U.S. in 2024 and expanded it into Europe the same year. In 2026, the company announced its first FDA clearance for a blind-sweep ultrasound AI tool, underscoring its push into AI-enabled imaging. More recently, Butterfly reported accelerating revenue growth in 2025 and early 2026, alongside progress on HomeCare commercialization and growing contributions from licensing and partnership revenue. In short, Butterfly Network remains a transformation story in digital health and ultrasound: attractive for its technology and platform potential, but still dependent on commercial execution, regulatory milestones, and its ability to scale adoption against strong competition.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
